Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure.

The Leiomyosarcoma – drugs in development research report provides a comprehensive overview on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Key Targets Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta
Key Mechanisms of action Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional
Key molecule types Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide
Major companies Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS

Key Targets in the Leiomyosarcoma Pipeline Drugs Market

In the Leiomyosarcoma pipeline drugs market the key targets are Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta. Vascular Endothelial Growth Factor Receptor 2 has the highest number of pipeline products.

Leiomyosarcoma Pipeline Drugs Market, by Targets

Leiomyosarcoma Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Leiomyosarcoma Pipeline Drugs Market

Vascular Endothelial Growth Factor Receptor 2 Inhibitor has the highest number of pipeline products followed by Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor.

Leiomyosarcoma Pipeline Drugs Market, by MoA

Leiomyosarcoma Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Leiomyosarcoma Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Leiomyosarcoma pipeline drugs market are Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional. Intravenous has the maximum number of pipeline products.

Leiomyosarcoma Pipeline Drugs Market Analysis, by RoA

Leiomyosarcoma Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Leiomyosarcoma Pipeline Drugs Market

In the Leiomyosarcoma pipeline drugs market the key molecule types are Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide.

Leiomyosarcoma Pipeline Drugs Market, by Molecule Types

Leiomyosarcoma Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Leiomyosarcoma Pipeline Drugs Market

The major companies in the Leiomyosarcoma pipeline drugs market are Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS.

Advenchen Laboratories LLC: It is a pharmaceutical company that offers healthcare solutions. The company conducts pharmaceutical research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others. Advenchen Laboratories provides services such as producing inhibitors for the treatment of human colon cancer, liver cancer, gastric cancer, lungs and breast cancer, among others. Advenchen Laboratories also provides customized chemical intermediate services. The company operates in China and the US. Advenchen Laboratories is headquartered in Moorpark, California, the US.

Leiomyosarcoma Pipeline Drugs Market, by Major Companies

Leiomyosarcoma Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Leiomyosarcoma Pipeline Drugs Market Overview

Key Targets Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta
Key Mechanisms of action Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional
Key molecule types Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide
Major companies Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Leiomyosarcoma

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

3SBio Inc
Actuate Therapeutics Inc
Advenchen Laboratories LLC
Agenus Inc
Alphamab Oncology
ALX Oncology Holdings Inc
Apexigen Inc
APIM Therapeutics AS
Apollomics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
BeiGene Ltd
BioAtla Inc
BioMed Valley Discoveries Inc
Calithera Biosciences Inc
Cebiotex SL
Clovis Oncology Inc
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ENB Therapeutics LLC
EUSA Pharma (UK) Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Immix BioPharma Inc
Immodulon Therapeutics Ltd
Incyte Corp
Karyopharm Therapeutics Inc
Kuur Therapeutics Ltd
Merck & Co Inc
Merck KGaA
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Philogen SpA
PTC Therapeutics Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Tactical Therapeutics Inc
Tempest Therapeutics Inc
Tessa Therapeutics Ltd
Viracta Therapeutics Inc
Y-mAbs Therapeutics Inc
Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leiomyosarcoma – Overview

Leiomyosarcoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leiomyosarcoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leiomyosarcoma – Companies Involved in Therapeutics Development

Leiomyosarcoma – Drug Profiles

Leiomyosarcoma – Dormant Projects

Leiomyosarcoma – Discontinued Products

Leiomyosarcoma – Product Development Milestones

Featured News & Press Releases

Nov 18, 2020: PTC Therapeutics announces key regulatory designations for PTC596 to advance treatment of two rare oncology indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Leiomyosarcoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Leiomyosarcoma – Pipeline by 3SBio Inc, 2022

Leiomyosarcoma – Pipeline by Actuate Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Advenchen Laboratories LLC, 2022

Leiomyosarcoma – Pipeline by Agenus Inc, 2022

Leiomyosarcoma – Pipeline by Alphamab Oncology, 2022

Leiomyosarcoma – Pipeline by ALX Oncology Holdings Inc, 2022

Leiomyosarcoma – Pipeline by Apexigen Inc, 2022

Leiomyosarcoma – Pipeline by APIM Therapeutics AS, 2022

Leiomyosarcoma – Pipeline by Apollomics Inc, 2022

Leiomyosarcoma – Pipeline by AstraZeneca Plc, 2022

Leiomyosarcoma – Pipeline by Atara Biotherapeutics Inc, 2022

Leiomyosarcoma – Pipeline by BeiGene Ltd, 2022

Leiomyosarcoma – Pipeline by BioAtla Inc, 2022

Leiomyosarcoma – Pipeline by BioMed Valley Discoveries Inc, 2022

Leiomyosarcoma – Pipeline by Calithera Biosciences Inc, 2022

Leiomyosarcoma – Pipeline by Cebiotex SL, 2022

Leiomyosarcoma – Pipeline by Clovis Oncology Inc, 2022

Leiomyosarcoma – Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Leiomyosarcoma – Pipeline by Eli Lilly and Co, 2022

Leiomyosarcoma – Pipeline by ENB Therapeutics LLC, 2022

Leiomyosarcoma – Pipeline by EUSA Pharma (UK) Ltd, 2022

Leiomyosarcoma – Pipeline by Exelixis Inc, 2022

Leiomyosarcoma – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Leiomyosarcoma – Pipeline by Immix BioPharma Inc, 2022

Leiomyosarcoma – Pipeline by Immodulon Therapeutics Ltd, 2022

Leiomyosarcoma – Pipeline by Incyte Corp, 2022

Leiomyosarcoma – Pipeline by Karyopharm Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Kuur Therapeutics Ltd, 2022

Leiomyosarcoma – Pipeline by Merck & Co Inc, 2022

Leiomyosarcoma – Pipeline by Merck KGaA, 2022

Leiomyosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Leiomyosarcoma – Pipeline by Pfizer Inc, 2022

Leiomyosarcoma – Pipeline by Pharma Mar SA, 2022

Leiomyosarcoma – Pipeline by Philogen SpA, 2022

Leiomyosarcoma – Pipeline by PTC Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022

Leiomyosarcoma – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Leiomyosarcoma – Pipeline by Tactical Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Tempest Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Tessa Therapeutics Ltd, 2022

Leiomyosarcoma – Pipeline by Viracta Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Y-mAbs Therapeutics Inc, 2022

Leiomyosarcoma – Pipeline by Yooyoung Pharm Co Ltd, 2022

Leiomyosarcoma – Dormant Projects, 2022

Leiomyosarcoma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Leiomyosarcoma, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Leiomyosarcoma pipeline drugs market?

    In the Leiomyosarcoma pipeline drugs market the key targets are Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta.

  • What are the key mechanisms of action in the Leiomyosarcoma pipeline drugs market?

    In the Leiomyosarcoma pipeline drugs market the key mechanisms of action are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor.

  • What are the key routes of administration in the Leiomyosarcoma pipeline drugs market?

    The key routes of administration in the Leiomyosarcoma pipeline drugs market are Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional.

  • What are the key molecule types in the Leiomyosarcoma pipeline drugs market?

    The key molecule types in the Leiomyosarcoma pipeline drugs market are Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide.

  • What are the major companies in the Leiomyosarcoma pipeline drugs market?

    In the Leiomyosarcoma pipeline drugs market the major companies are Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS.

Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.